Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Electronic Health Records | 13 | 2021 | 3492 | 1.20 | Why? |
| Publication Bias | 1 | 2021 | 241 | 0.80 | Why? |
| Systematized Nomenclature of Medicine | 1 | 2018 | 30 | 0.78 | Why? |
| Supervised Machine Learning | 2 | 2017 | 172 | 0.74 | Why? |
| Observational Studies as Topic | 3 | 2021 | 1887 | 0.71 | Why? |
| International Classification of Diseases | 1 | 2018 | 265 | 0.61 | Why? |
| Drug Therapy | 1 | 2018 | 280 | 0.61 | Why? |
| Data Mining | 2 | 2018 | 767 | 0.57 | Why? |
| Models, Statistical | 6 | 2021 | 5312 | 0.56 | Why? |
| Endocrine System | 1 | 2014 | 67 | 0.55 | Why? |
| Phenotype | 7 | 2019 | 4037 | 0.49 | Why? |
| Databases, Factual | 8 | 2021 | 6248 | 0.48 | Why? |
| Patient Readmission | 2 | 2021 | 1543 | 0.47 | Why? |
| Self Efficacy | 1 | 2017 | 717 | 0.44 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.43 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 1261 | 0.41 | Why? |
| Glucose | 1 | 2014 | 573 | 0.40 | Why? |
| Self Care | 1 | 2017 | 918 | 0.38 | Why? |
| Reproducibility of Results | 4 | 2021 | 11304 | 0.38 | Why? |
| Calibration | 2 | 2018 | 307 | 0.32 | Why? |
| Information Dissemination | 2 | 2021 | 2986 | 0.30 | Why? |
| Pharmaceutical Preparations | 1 | 2018 | 1897 | 0.26 | Why? |
| Bias | 2 | 2019 | 1109 | 0.25 | Why? |
| Machine Learning | 1 | 2018 | 4395 | 0.23 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.22 | Why? |
| Intubation | 2 | 2020 | 437 | 0.22 | Why? |
| Psychoses, Substance-Induced | 1 | 2021 | 91 | 0.21 | Why? |
| Regression Analysis | 2 | 2018 | 2484 | 0.20 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2017 | 6166 | 0.19 | Why? |
| Vocabulary, Controlled | 1 | 2018 | 26 | 0.19 | Why? |
| Systems Integration | 1 | 2018 | 72 | 0.18 | Why? |
| Piracetam | 1 | 2017 | 6 | 0.18 | Why? |
| Phenytoin | 1 | 2017 | 17 | 0.18 | Why? |
| Chemotherapy, Adjuvant | 1 | 2021 | 606 | 0.18 | Why? |
| Monophenol Monooxygenase | 1 | 2017 | 11 | 0.17 | Why? |
| Lipoprotein(a) | 1 | 2018 | 92 | 0.17 | Why? |
| Area Under Curve | 3 | 2021 | 2564 | 0.17 | Why? |
| Patient-Specific Modeling | 1 | 2017 | 60 | 0.17 | Why? |
| Exome | 1 | 2018 | 207 | 0.16 | Why? |
| New York City | 6 | 2021 | 7432 | 0.16 | Why? |
| Melanins | 1 | 2017 | 42 | 0.16 | Why? |
| Genetic Diseases, Inborn | 1 | 2018 | 190 | 0.16 | Why? |
| Data Curation | 1 | 2017 | 144 | 0.16 | Why? |
| Angioedema | 1 | 2017 | 111 | 0.15 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.14 | Why? |
| Data Interpretation, Statistical | 1 | 2019 | 657 | 0.14 | Why? |
| Behavior Therapy | 1 | 2017 | 235 | 0.14 | Why? |
| Computational Biology | 3 | 2019 | 4514 | 0.14 | Why? |
| Diagnosis, Computer-Assisted | 1 | 2019 | 436 | 0.13 | Why? |
| Pharmacovigilance | 1 | 2018 | 501 | 0.13 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.13 | Why? |
| Publications | 1 | 2018 | 463 | 0.13 | Why? |
| Coronary Disease | 1 | 2018 | 645 | 0.12 | Why? |
| Renal Replacement Therapy | 1 | 2021 | 1530 | 0.12 | Why? |
| Suicidal Ideation | 1 | 2021 | 1226 | 0.12 | Why? |
| Blood Glucose Self-Monitoring | 1 | 2017 | 791 | 0.12 | Why? |
| Computer Simulation | 2 | 2019 | 4982 | 0.12 | Why? |
| Dyslipidemias | 1 | 2018 | 791 | 0.11 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.11 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.11 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.11 | Why? |
| Mobile Health Units | 1 | 2018 | 741 | 0.11 | Why? |
| Biomarkers | 1 | 2014 | 23361 | 0.11 | Why? |
| Medical Informatics | 1 | 2018 | 648 | 0.10 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.10 | Why? |
| Humans | 33 | 2021 | 930598 | 0.10 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.10 | Why? |
| Academic Medical Centers | 2 | 2020 | 3088 | 0.10 | Why? |
| Influenza, Human | 4 | 2021 | 10779 | 0.10 | Why? |
| Documentation | 1 | 2012 | 332 | 0.10 | Why? |
| United States | 10 | 2021 | 46150 | 0.10 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.09 | Why? |
| Republic of Korea | 4 | 2021 | 5858 | 0.09 | Why? |
| Suicide | 1 | 2021 | 1500 | 0.09 | Why? |
| Autoimmune Diseases | 1 | 2021 | 1996 | 0.09 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.08 | Why? |
| Quality Assurance, Health Care | 1 | 2012 | 596 | 0.08 | Why? |
| Algorithms | 3 | 2019 | 7346 | 0.08 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.08 | Why? |
| Information Storage and Retrieval | 1 | 2012 | 644 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Arrhythmias, Cardiac | 1 | 2020 | 2510 | 0.08 | Why? |
| Antirheumatic Agents | 1 | 2021 | 3023 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2017 | 1881 | 0.08 | Why? |
| Electrocardiography | 1 | 2020 | 3957 | 0.08 | Why? |
| Spain | 5 | 2021 | 15545 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.07 | Why? |
| Risk | 1 | 2017 | 5288 | 0.07 | Why? |
| Epilepsy | 1 | 2017 | 1401 | 0.07 | Why? |
| Adolescent | 8 | 2021 | 86841 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.06 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.06 | Why? |
| Cohort Studies | 6 | 2021 | 36005 | 0.06 | Why? |
| Male | 16 | 2021 | 367725 | 0.06 | Why? |
| Blood Glucose | 1 | 2017 | 3642 | 0.06 | Why? |
| Female | 16 | 2021 | 380317 | 0.06 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.06 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.06 | Why? |
| Administrative Claims, Healthcare | 1 | 2021 | 124 | 0.06 | Why? |
| Current Procedural Terminology | 1 | 2019 | 10 | 0.05 | Why? |
| Aged | 10 | 2021 | 215776 | 0.05 | Why? |
| Adult | 11 | 2021 | 244371 | 0.05 | Why? |
| Public Policy | 1 | 2012 | 1894 | 0.05 | Why? |
| Fluoroquinolones | 1 | 2021 | 235 | 0.05 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.05 | Why? |
| Ceftriaxone | 1 | 2021 | 365 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.05 | Why? |
| Quantitative Trait, Heritable | 1 | 2018 | 26 | 0.05 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.05 | Why? |
| Hospital Information Systems | 1 | 2019 | 115 | 0.04 | Why? |
| Nutrition Surveys | 1 | 2019 | 287 | 0.04 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2021 | 1008 | 0.04 | Why? |
| Hypertension | 1 | 2019 | 8895 | 0.04 | Why? |
| American Heart Association | 1 | 2019 | 347 | 0.04 | Why? |
| Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2017 | 64 | 0.04 | Why? |
| Pedigree | 1 | 2018 | 502 | 0.04 | Why? |
| Models, Biological | 1 | 2014 | 4907 | 0.04 | Why? |
| Depression | 1 | 2021 | 14116 | 0.04 | Why? |
| Social Media | 1 | 2018 | 5798 | 0.04 | Why? |
| Cerebral Infarction | 1 | 2019 | 245 | 0.04 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.04 | Why? |
| Learning Curve | 1 | 2017 | 157 | 0.04 | Why? |
| Proton Magnetic Resonance Spectroscopy | 1 | 2017 | 159 | 0.04 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.04 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.04 | Why? |
| Germany | 2 | 2021 | 9196 | 0.04 | Why? |
| Confidence Intervals | 1 | 2018 | 744 | 0.04 | Why? |
| Probability | 1 | 2019 | 923 | 0.04 | Why? |
| Family Relations | 1 | 2018 | 288 | 0.04 | Why? |
| Genetic Testing | 1 | 2018 | 395 | 0.04 | Why? |
| Prevalence | 3 | 2021 | 25773 | 0.03 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.03 | Why? |
| Observer Variation | 1 | 2017 | 622 | 0.03 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.03 | Why? |
| Renal Insufficiency, Chronic | 2 | 2019 | 2654 | 0.03 | Why? |
| Community Networks | 1 | 2017 | 342 | 0.03 | Why? |
| Enoxaparin | 1 | 2021 | 1064 | 0.03 | Why? |
| Gene Frequency | 1 | 2018 | 1210 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Safety | 1 | 2021 | 1583 | 0.03 | Why? |
| Infant | 3 | 2021 | 30274 | 0.03 | Why? |
| Diagnostic Errors | 1 | 2019 | 865 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Databases, Genetic | 1 | 2018 | 1127 | 0.03 | Why? |
| Datasets as Topic | 1 | 2019 | 1404 | 0.03 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Bibliometrics | 1 | 2019 | 731 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.03 | Why? |
| Age Distribution | 1 | 2021 | 3567 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2018 | 1648 | 0.03 | Why? |
| Drug Combinations | 1 | 2021 | 3852 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2017 | 1165 | 0.03 | Why? |
| Child | 4 | 2021 | 70012 | 0.03 | Why? |
| Health Care Surveys | 1 | 2019 | 2942 | 0.02 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.02 | Why? |
| Efficiency, Organizational | 1 | 2012 | 482 | 0.02 | Why? |
| Insulin | 1 | 2017 | 1316 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.02 | Why? |
| Arthritis, Rheumatoid | 1 | 2021 | 2043 | 0.02 | Why? |
| Self Report | 1 | 2019 | 3802 | 0.02 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.02 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2021 | 7220 | 0.02 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.02 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.02 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Vitamin D | 1 | 2021 | 2904 | 0.02 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.02 | Why? |
| Atrial Fibrillation | 1 | 2019 | 2320 | 0.02 | Why? |
| France | 1 | 2021 | 12074 | 0.02 | Why? |
| Cardiology | 1 | 2019 | 2873 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2019 | 9537 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Myocardial Infarction | 1 | 2019 | 3361 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Workflow | 1 | 2012 | 2373 | 0.02 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.02 | Why? |
| Models, Molecular | 1 | 2017 | 7616 | 0.02 | Why? |
| Europe | 1 | 2019 | 12702 | 0.01 | Why? |
| Continuity of Patient Care | 1 | 2012 | 1574 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2019 | 3893 | 0.01 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Molecular Docking Simulation | 1 | 2017 | 6902 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Research | 1 | 2012 | 2115 | 0.01 | Why? |
| Guidelines as Topic | 1 | 2012 | 2844 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2019 | 22971 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| China | 1 | 2021 | 50654 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |